Amphastar Pharmaceuticals Inc has a consensus price target of $52.57 based on the ratings of 8 analysts. The high is $70 issued by Jefferies on July 25, 2023. The low is $32 issued by Piper Sandler on March 21, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Piper Sandler, and Wells Fargo on March 21, 2025, February 4, 2025, and November 22, 2024, respectively. With an average price target of $41 between Piper Sandler, Piper Sandler, and Wells Fargo, there's an implied 74.47% upside for Amphastar Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/10/2025 | Buy Now | — | Needham | Serge Belanger62% | — | Reiterates | Hold → Hold | Get Alert |
03/21/2025 | Buy Now | 36.17% | Piper Sandler | David Amsellem69% | $36 → $32 | Maintains | Neutral | Get Alert |
02/04/2025 | Buy Now | 53.19% | Piper Sandler | David Amsellem69% | $66 → $36 | Downgrade | Overweight → Neutral | Get Alert |
11/22/2024 | Buy Now | 134.04% | Wells Fargo | Joe Quatrochi35% | → $55 | Initiates | → Overweight | Get Alert |
08/08/2024 | Buy Now | 180.85% | Piper Sandler | David Amsellem69% | $71 → $66 | Maintains | Overweight | Get Alert |
08/08/2024 | Buy Now | — | Needham | Serge Belanger62% | — | Reiterates | → Hold | Get Alert |
06/27/2024 | Buy Now | 202.13% | Piper Sandler | David Amsellem69% | $71 → $71 | Reiterates | Overweight → Overweight | Get Alert |
05/22/2024 | Buy Now | — | Needham | Serge Belanger62% | — | Reiterates | → Hold | Get Alert |
05/09/2024 | Buy Now | — | Needham | Serge Belanger62% | — | Reiterates | → Hold | Get Alert |
04/10/2024 | Buy Now | — | Needham | Serge Belanger62% | — | Reiterates | → Hold | Get Alert |
03/05/2024 | Buy Now | 155.32% | JP Morgan | Ekaterina Knyazkova28% | → $60 | Initiates | → Overweight | Get Alert |
11/17/2023 | Buy Now | 168.09% | B of A Securities | Jason Gerberry61% | → $63 | Initiates | → Neutral | Get Alert |
07/25/2023 | Buy Now | 197.87% | Jefferies | Glen Santangelo50% | → $70 | Reinstates | Buy → Buy | Get Alert |
05/17/2023 | Buy Now | 87.23% | Wells Fargo | Jacob Hughes43% | $40 → $44 | Maintains | Equal-Weight | Get Alert |
10/25/2022 | Buy Now | 70.21% | Piper Sandler | David Amsellem69% | $43 → $40 | Maintains | Overweight | Get Alert |
10/21/2022 | Buy Now | 53.19% | Jefferies | Glen Santangelo50% | → $36 | Assumes | → Buy | Get Alert |
07/29/2022 | Buy Now | 87.23% | Capital One | Tim Chiang38% | → $44 | Initiates | → Overweight | Get Alert |
The latest price target for Amphastar Pharma (NASDAQ:AMPH) was reported by Needham on April 10, 2025. The analyst firm set a price target for $0.00 expecting AMPH to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Amphastar Pharma (NASDAQ:AMPH) was provided by Needham, and Amphastar Pharma reiterated their hold rating.
There is no last upgrade for Amphastar Pharma
The last downgrade for Amphastar Pharmaceuticals Inc happened on February 4, 2025 when Piper Sandler changed their price target from $66 to $36 for Amphastar Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a reiterated with a price target of $0.00 to $0.00. The current price Amphastar Pharma (AMPH) is trading at is $23.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.